Immunome Inc. (IMNM) stock
IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.18−0.43 (-2.44%)
Close on Nov 17, 2026Market cap $1.95BP/E –Yield –
Immunome operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Immunome's operating cash flow for the twelve months ending Mar 31, 2026 was -$196.50M. For fiscal 2025 it was -$190.92M. The highest annual figure on record is -$7.57M in fiscal 2023.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$190.92M | – |
| FY2024 | Dec 31, 2024 | -$110.79M | – |
| FY2023 | Dec 31, 2023 | -$7.57M | – |
| FY2022 | Dec 31, 2022 | -$28.69M | – |
| FY2021 | Dec 31, 2021 | -$18.23M | – |
| FY2020 | Dec 31, 2020 | -$12.13M | – |
| FY2019 | Dec 31, 2019 | -$9.60M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$58.64M | – |
| Q4 FY2025 | Dec 31, 2025 | -$47.95M | – |
| Q3 FY2025 | Sep 30, 2025 | -$40.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$49.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$53.06M | – |
| Q4 FY2024 | Dec 31, 2024 | -$42.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.40M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.17M | -146.2% |
| Q4 FY2023 | Dec 31, 2023 | -$17.46M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.61M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.67M | – |
| Q1 FY2023 | Mar 31, 2023 | $24.17M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.68M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.38M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.15M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.74M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.54M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.06M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.48M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.06M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.58M | – |
See a number that looks wrong?